Mesoblast Limited (NASDAQ:MESO) Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ET
Company Participants
Silviu Itescu – Chief Executive Officer & Managing Director
Andrew Chaponnel – Interim Chief Financial Officer
Marcelo Santoro – Chief Commercial Officer
Conference Call Participants
Edward Tenthoff – Piper Sandler
Michael Okunewitch – Maxim Group
Silviu Itescu
Good morning, everybody. I’m Silviu Itescu. I’m the Chief Executive of Mesoblast. Together with me this morning is Marcelo Santoro our Chief Commercial Officer; and Andrew Chaponnel, our Interim Chief Financial Officer. Today, we’re presenting our financial results and operational update for the half year ended December 31, 2024.
We could go to Slide 4, please. Mesoblast is the global leader in allogeneic cellular medicines for inflammatory diseases. We have one product already FDA approved, RYONCIL. We have multiple locations globally. We’re listed duly on the ASX and NASDAQ. We have more than 1,000 patents and patent applications that support our products. Beyond our first approved product, RYONCIL, we have two other major products in Phase III, and we have a whole pipeline sitting behind these. We have scalable manufacturing that have been FDA inspected, and we have a supply chain capability that allows us to meet the global needs commercially.
Next slide, please. Our platform technology is based on a shared mechanism of action across all of our products. Our mesenchymal lineage precursor/stromal cells are highly purified to very high concentrations in final cryopreserved vials. These cells have on their surface a range of receptors for inflammatory cytokines, including interferon gamma, TNF, IL-17, IL-6 and IL-1 and others. And when the cells are placed in regions of severe inflammation where these cytokines play major disease roles, they’re able to respond to inflammation with the release of multiple anti-inflammatory factors that act in concert to turn of the damaging inflammation that results in severe diseases and potentially
